Opa1 deficiency in a mouse model of dominant optic atrophy leads to retinal ganglion cell dendropathy

Brain

Volumn 133, Issue 10, 2010, Pages 2942-2951

  Williams, Pete A ^a   Morgan, James E ^a,b   Votruba, Marcela ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

dendrite; dominant optic atrophy; mitochondria; Opa1; retinal ganglion cells

Indexed keywords

CARBOCYANINE; OPA1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; GUANOSINE TRIPHOSPHATASE; OPA1 PROTEIN (GTPASE), MOUSE;

AGE DISTRIBUTION; AGING; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT OPTIC ATROPHY; CELL LOSS; CELL STRUCTURE; CONTROLLED STUDY; DENDRITE; DISEASE EXACERBATION; MITOCHONDRION; MOUSE; NERVE CELL DEGENERATION; NONHUMAN; OPA1 DEFICIENCY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; QUANTITATIVE ANALYSIS; RETINA GANGLION CELL; RETINA INNER PLEXIFORM LAYER; RETINAL GANGLION CELL DENDROPATHY; SEX DIFFERENCE; WILD TYPE; ANIMAL; ATROPHY; CELL COUNT; GENETICS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; ATROPHY; CELL COUNT; DENDRITES; GTP PHOSPHOHYDROLASES; MICE; MICE, TRANSGENIC; OPTIC ATROPHY, AUTOSOMAL DOMINANT; RETINAL GANGLION CELLS;

EID: 77957683695     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq218     Document Type: Article

References (45)

1. Aijaz S, Erskine L, Jeffery G, Bhattacharya SS, Votruba M. Developmental expression profile of the optic atrophy gene product: OPA1 is not localized exclusively in the mammalian retinal ganglion cell layer. Invest Ophthalmol Vis Sci 2004; 45: 1667-73.
2. Alavi MV, Bette S, Schimpf S, Schuettauf F, Schraermeye U, Wehrl HF, et al. A splice site mutation in the murine Opa1 gene features pathology of autosomal dominant optic atrophy. Brain 2007; 130: 1029-42.
3. Alexander C, Votruba M, Pesch UE, Thiselton DL, Mayer S, Moore A, et al. OPA1, encoding a dynamin-related GTPase, is mutated in auto-somal dominant optic atrophy linked to chromosome 3q28. Nat Genet 2000; 26: 211-15.
4. Amati-Bonneau P, Valentino ML, Reynier P, Gallardo ME, Bornstein B, Boissière A, et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes. Brain 2008; 131: 338-51.
5. Arnoult D, Grodet A, Lee YJ, Estaquier J, Blackstone C. Release of OPA1 during apoptosis participates in the rapid and complete release of cytochrome c and subsequent mitochondrial fragmentation. J Biol Chem 2005; 280: 35742-50.
6. Berninger TA, Jaeger W, Krastel H. Electrophysiology and colour perim-etry in dominant infantile optic atrophy. Br J Ophthalmol 1991; 75: 49-52.
7. Carelli V, La Morgia C, Iommarini L, Carroccia R, Mattiazzi M, Sangiorgi S, et al. Mitochondrial optic neuropathies: how two genomes may kill the same cell type? Biosci Rep 2007; 27: 173-84.
8. Carelli V, Ross-Cisneros FN, Sadun AA. Optic nerve degeneration and mitochondrial dysfunction: genetic and acquired optic neuropathies. Neurochem Int 2002; 40: 573-84.
9. Chen H, Chomyn A, Chan DC. Disruption of fusion results in mitochon-drial heterogeneity and dysfunction. J Biol Chem 2005; 280: 26185-92.
10. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 2003; 160: 189-200.
11. Chen H, McCaffery JM, Chan DC. Mitochondrial fusion protects against neurodegeneration in the cerebellum. Cell 2007; 130: 548-62.
12. Cook AM, Whitlow J, Hatton J, Young B. Cyclosporine A for neuropro-tection: establishing dosing guidelines for safe and effective use. Expert Opin Drug Saf 2009; 8: 411-19.
13. Davies VJ, Hollins AJ, Piechota MJ, Yip W, Davies JR, White KE, et al. Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function. Hum Mol Genet 2007; 1: 1307-18.
14. Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P, et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet 2000; 26: 207-10.
15. Ferre M, Amati-Bonneau P, Tourmen Y, Malthiery Y, Reynier P. eOPA1: an online database for OPA1 mutations. Hum Mutat 2005; 25: 423-8.
16. Gan WB, Grutzendler J, Wong WT, Wong RO, Lichtman JW. Multicolor "diolistic" labeling of the nervous system using lipophilic dye combinations. Neuron 2000; 27: 219-25.
17. Gutierrez H, Davies AM. A fast and accurate procedure for deriving the Sholl profile in quantitative studies of neuronal morphology. J Neurosci Methods 2007; 163: 24-30.
18. Heiduschka P, Schnichels S, Fuhrmann N, Hofmeister S, Schraermeyer U, Wissinger B, et al. Retinal ganglion cells are primarily affected in an animal model of OPA1 associated autosomal dominant optic atrophy. Invest Ophthalmol Vis Sci 2009. Advance Access published on October, 15, doi:10.1167/iovs.09-3606.
19. Holder GE, Votruba M, Carter AC, Bhattacharya SS, Fitzke FW, Moore AT. Electrophysiological findings in dominant optic atrophy (DOA) linking to the OPA1 locus on chromosome 3q 28-qter. Doc Ophthalmol 1998; 95: 217-28.
20. Kaeberlein M. Resveratrol and rapamycin: are they anti-aging drugs? Bioessays 2010; 32: 96-9.
21. Kanazawa T, Zappaterra MD, Hasegawa A, Wright AP, Newman-Smith ED, Buttle KF, et al. The C. elegans Opa1 homologue EAT-3 is essential for resistance to free radicals. PLoS Genet 2008; 4: e1000022.
22. Kerr DS. Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Mol Genet Metab 2010; 99: 246-55.
23. Kjer P, Jensen OA, Klinken L. Histopathology of eye, optic nerve and brain in a case of dominant optic atrophy. Acta Ophthalmol (Copenh) 1983; 61: 300-12.
24. Levin LA. Axonal loss and neuroprotection in optic neuropathies. Can J Ophthalmol 2007; 42: 403-8.
25. Li Z, Okamoto K, Hayashi Y, Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004; 119: 873-87.
26. Marc RE. Functional anatomy of the neural retina. In: Albert DM, Miller JW, Azar DT, editors. Albert & Jakobiec's principles and practice of ophthalmology. Vol. 2. Philadelphia, PA: Saunders/Elsevier; 2008. Chapter 122. p. 1-28.
27. Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci 2006; 7: 278-94.
28. Nakajima Y, Inokuchi Y, Nishi M, Shimazawa M, Otsubo K, Hara H. Coenzyme Q protects retinal cell s against oxidative stress in vitro and in vivo. Brain Res 2008; 1226: 226-33.
29. Olichon A, Landes T, Arnauné-Pelloquin L, Emorine LJ, Mils V, Guichet A, et al. Effects of OPA1 mutations on mitochondrial morphology and apoptosis: relevance to ADOA pathogenesis. J Cell Physiol 2007; 211: 423-30.
30. Palau F, Estela A, Pla-Mart?́n D, Sánchez-Piris M. The role of mitochon-drial network dynamics in the pathogenesis of Charcot-Marie-Tooth disease. Adv Exp Med Biol 2009; 52: 129-37.
31. Pignatelli V, Strettoi E. Bipolar cells of the mouse retina: a gene gun, morphological study. J Comp Neurol 2004; 476: 254-66.
32. Pourcho RG. Neurotransmitters in the retina. Curr Eye Res 1996; 15: 797-803.
33. Shimazawa M, Yamashimab T, Agarwalc N, Hara H. Neuroprotective effects of minocycline against in vitro and in vivo retinal ganglion cell damage. Brain Res 2005; 1053: 185-94.
34. Sholl DA. Dendritic organization in the neurons of the visual and motor cortices of the cat. J Anat 1953; 97: 387-406.
35. Sun W, Li N, He S. Large-scale morphological survey of mouse retinal ganglion cells. J Comp Neurol 2002; 451: 115-26.
36. Tang S, Le PK, Tse S, Wallace DC, Huang T. Heterozygous mutation of Opa1 in Drosophila shortens lifespan mediated through increased reactive oxygen species production. PLoS One 2009; 4: e4492.
37. Tatsuta T, Langer T. Quality control of mitochondria: protection against neurodegeneration and ageing. EMBO J 2008; 27: 306-14.
38. Twig G, Elorza A, Molina AJ, Mohamed H, Wikstrom JD, Walzer G, et al. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J 2008; 27: 433-46.
39. Votruba M, Fitzke FW, Holder GE, Carter A, Bhattacharya SS, Moore AT. Clinical features in affected individuals from 21 pedigrees with dominant optic atrophy. Arch Ophthalmol 1998; 116: 351-8.
40. Waterham HR, Koster J, van Roermund CW, Mooyer PAW, Wanders RJA, Leonard JV. A lethal defect of mitochondrial and per-oxisomal fission. N Engl J Med 2007; 356: 1736-41.
41. White KE, Davies VJ, Hogan VE, Piechota MJ, Nichols PP, Turnbull DM, et al. OPA1 deficiency associated with increased autophagy in retinal ganglion cells in a murine model of dominant optic atrophy. Invest Ophthalmol Vis Sci 2009; 50: 2567-71.
42. Xu HP, Tian N. Retinal ganglion cell dendrites undergo a visual activity-dependent redistribution after eye opening. J Comp Neurol 2007; 503: 244-59.
43. Yarosh W, Monserrate J, Tong JJ, Tse S, Le PK, Nguyen K, et al. The molecular mechanisms of OPA1-mediated optic atrophy in Drosophila model and prospects for antioxidant treatment. PLoS Genet 2008; 4: e6.
44. Yu-Wai-Man CY, Chinnery PF, Griffiths PG. Optic neuropathies-importance of spatial distribution of mitochondria as well as function. Med Hypotheses 2005; 65: 1038-42.
45. Yu-Wai-Man P, Davies VJ, Piechota MJ, Cree LM, Votruba M, Chinnery PF. Secondary mtDNA defects do not cause optic nerve dysfunction in a mouse model of dominant optic atrophy. Invest Ophthalmol Vis Sci 2009; 14: 4561-6.